Literature DB >> 32181937

Psychiatric and neurocognitive consequences of endogenous hypercortisolism.

M Piasecka1,2, E Papakokkinou1,2, E Valassi3,4, A Santos3,4, S M Webb3,4, F de Vries5, A M Pereira5, O Ragnarsson1,2.   

Abstract

Psychiatric and neurocognitive symptoms due to hypercortisolism were already described by Harvey Cushing in his original paper on patients with Cushing's syndrome (CS). Nowadays, it is well known that psychiatric and cognitive complaints are two of the most common, and most distressing, symptoms in patients with CS. Psychiatric symptoms are indeed a major clinical manifestation of CS. The most commonly observed psychiatric conditions are depression and anxiety, whilst mania and psychosis are less common. Several domains of cognitive function are impaired at diagnosis, including episodic and working memory, executive function and attention. Following treatment, one-fourth of the patients still experience depressed mood, and the cognitive impairments are only partially restored. Consequently, quality of life in patients with CS is severely and persistently affected. Neuroimaging studies have also illustrated the deleterious effects of hypercortisolism on the brain by demonstrating reduced grey matter volumes and cortical thickness, altered resting-state functional responses and during cognitive tasks, as well as widespread reduced white matter integrity, especially in structures important for cognitive function and emotional processing, both before and after successful abrogation of hypercortisolism. In this paper, we summarize the current knowledge on the psychiatric and neurocognitive consequences of hypercortisolism in patients with CS, both before, and after successful treatment. In addition, we review the structural and functional brain abnormalities associated with hypercortisolism and discuss the influence of these factors on quality of life.
© 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.

Entities:  

Keywords:  Cushing’s syndrome; cognitive dysfunction; depression; neuroimaging; quality of life

Mesh:

Substances:

Year:  2020        PMID: 32181937     DOI: 10.1111/joim.13056

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  9 in total

Review 1.  Quality of life impairment after a diagnosis of Cushing's syndrome.

Authors:  Susan M Webb; Elena Valassi
Journal:  Pituitary       Date:  2022-06-29       Impact factor: 3.599

Review 2.  Alterations in Immune-Related Defensin Alpha 4 (DEFA4) Gene Expression in Health and Disease.

Authors:  Fatemah Basingab; Abeer Alsaiary; Shahad Almontashri; Aisha Alrofaidi; Mona Alharbi; Sheren Azhari; Khloud Algothmi; Safiah Alhazmi
Journal:  Int J Inflam       Date:  2022-05-28

3.  Salivary cortisol is associated with cognitive changes in patients with fibromyalgia.

Authors:  Yi-Ju Lin; Yu-Chieh Ko; Lok-Hi Chow; Fu-Jung Hsiao; Hung-Yu Liu; Pei-Ning Wang; Wei-Ta Chen
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

4.  Brain mineralocorticoid receptor in health and disease: From molecular signalling to cognitive and emotional function.

Authors:  Susana N Paul; Katja Wingenfeld; Christian Otte; Onno C Meijer
Journal:  Br J Pharmacol       Date:  2022-04-07       Impact factor: 9.473

5.  Impaired quality of life, but not cognition, is linked to a history of chronic hypercortisolism in patients with Cushing's disease in remission.

Authors:  Emilie Pupier; Alicia Santos; Nicole Etchamendy; Aurélie Lavielle; Amandine Ferriere; Aline Marighetto; Eugenia Resmini; Daniela Cota; Susan M Webb; Antoine Tabarin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-08       Impact factor: 6.055

6.  The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality.

Authors:  Padiporn Limumpornpetch; Ann W Morgan; Ana Tiganescu; Paul D Baxter; Victoria Nyawira Nyaga; Mar Pujades-Rodriguez; Paul M Stewart
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

Review 7.  Long-term effects of glucocorticoid excess on the brain.

Authors:  Alies J Dekkers; Jorge Miguel Amaya; Merel van der Meulen; Nienke R Biermasz; Onno C Meijer; Alberto M Pereira
Journal:  J Neuroendocrinol       Date:  2022-08-18       Impact factor: 3.870

8.  Psychotropic Drugs in Patients with Cushing's Disease Before Diagnosis and at Long-Term Follow-Up: A Nationwide Study.

Authors:  Daniel Bengtsson; Oskar Ragnarsson; Katarina Berinder; Per Dahlqvist; Britt Edén Engström; Bertil Ekman; Charlotte Höybye; Pia Burman; Jeanette Wahlberg
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

Review 9.  Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside.

Authors:  Vittoria Favero; Arianna Cremaschi; Chiara Parazzoli; Alberto Falchetti; Agostino Gaudio; Luigi Gennari; Alfredo Scillitani; Fabio Vescini; Valentina Morelli; Carmen Aresta; Iacopo Chiodini
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.